ClinicalTrials.gg
RecruitingNCT06982729Updated Nov 17, 2025

Study of YK012 in Primary Membranous Nephropathy

A Phase 1 interventional study of YK012 in Primary Membranous Nephropathy, sponsored by Excyte Biopharma Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Excyte Biopharma Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Glomerulonephritis, Membranous with a site in China — 29 open to participants now, 37 under way, 10 of them phase 3. Glomerulonephritis, Membranous · China.

Planned enrollment
27th of 50
72 · median 77
Started
2025
with 7 others
Phase 1
7 of 60
6 open now
Primary completion
2026-12
later than 13 of 36 live
Registered
45th of 60
by date

Among the 60 studies in Glomerulonephritis, Membranous with a site in China, this one is the 27th largest by planned enrollment of the 50 interventional ones that give a count, is one of 8 that started in 2025, is one of 7 in phase 1, reaches primary completion later than 13 of the 36 other live ones, and was the 45th registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

29 of the 60 studies in Glomerulonephritis, Membranous with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 14 (34%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Glomerulonephritis, Membranous with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (PMN).

Read the detailed description

This clinical trial consists of Phase Ia and Phase Ib. The goal of phase Ia is to evaluate the safety and tolerability of YK012 in participants with primary membranous nephropathy and to determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE). The goal of phase Ib is to assess the preliminary efficacy of YK012 in participants with primary membranous nephropathy and to establish the recommended Phase II dose (RP2D).

03

Conditions studied

  • Primary Membranous Nephropathy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 80 years (inclusive), regardless of gender.
  • Kidney -confirmed diagnosis of primary (idiopathic) membranous nephropathy within the past 10 years.
  • Elevated 24-hour urine protein, meeting the pre-defined criteria.
  • Estimated (eGFR) ≥60 mL/min/1.73m² as calculated by the CKD-EPI equation.
  • If currently taking an angiotensin-converting enzyme inhibitor (ACEi), angiotensin II receptor blocker (ARB), or sodium-glucose cotransporter-2 (SGLT-2) inhibitor, the dose must have been stable for at least 4 weeks prior to enrollment or since initiation of therapy.
  • Laboratory test results must meet the predefined criteria within 7 days prior to enrollment.
  • Capable of understanding and voluntarily participating in this clinical trial, having provided written , and able to comply with scheduled visits, treatments, examinations, and other study procedures as required.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of secondary membranous nephropathy.
  • Any prior receipt of protocol-specified pharmacological treatment for membranous nephropathy.
  • History of within 5 years prior to enrollment.
  • Poorly controlled hypertension at enrollment.
  • Severe renal dysfunction with prior dialysis or kidney transplantation within 6 months prior to enrollment.
  • Prior kidney -confirmed diagnosis of diabetic nephropathy.
  • History of severe or chronic infections within the 6 months before enrollment or current need for systemic antibiotic or antiviral therapy.
  • Cardiovascular or cerebrovascular events requiring hospitalization within 6 months prior to enrollment.
  • Severe or poorly controlled comorbidities that may affect protocol compliance or efficacy evaluation.
  • Active Tuberculosis (TB) with documented evidence of infection.
  • History of solid organ or bone marrow transplantation.
  • , major surgery, or participated in other clinical trials with drug use within 28 days prior to enrollment.
  • -positive, or HBcAb-positive with detectable HBV DNA above the normal range; antibody-positive; seropositive; Treponema pallidum antibody-positive.
  • \<200 cells/μL
  • Known to any component of YK012.
  • Pregnancy, breastfeeding, or positive pregnancy test at screening; or plans to become pregnant during the trial or within 12 months after study completion, or unwillingness to use physical methods during the study and for 12 months thereafter.
  • Other conditions deemed by the investigator to make the subject unsuitable for participation in this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Ia: YK012

    Participants with primary membranous nephropathy will receive ascending doses of YK012 infusion to evaluate the safety and tolerability of YK012

    Drug: YK012

  • Experimental
    Ib: YK012

    Participants will receive 2 different doses of YK012 infusion to assess the preliminary efficacy of YK012 in participants with primary membranous nephropathy and to establish the recommended Phase II dose (RP2D).

    Drug: YK012

Interventions

  • DrugYK012

    YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells

    Also known as: YK012 Infusion

06

What researchers measure

Primary outcomes

  1. Ia: Dose-limiting Toxicity(DLT)

    Dose-limiting toxicities (DLTs) is defined as adverse events occurring within 28 days after the first dose and assessed by the investigator as related to the Investigational Medicinal Product (IMP).

    Time frame: up to 28 days after the first dose

  2. Ia: Adverse Event (AE)

    An AE is defined as any untoward medical event that occurs after a participant receives the investigational drug, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the investigational drug.

    Time frame: From the first induction to the end of the trial at 53 weeks

  3. Ia: Severe Adverse Event

    An SAE refers to any untoward medical occurrence after the participant receives the IMP that results in one or more of the following: death, life-threatening event, permanent or serious disability or loss of function, hospitalization or prolongation of hospitalization, congenital abnormalities or birth defects.

    Time frame: From the first induction to the end of the trial at 53 weeks

  4. Ib: Proportion of participants achieving overall response

    Time frame: From enrollment to the end of the trial at 76 weeks (if applicable)

Secondary outcomes

  1. Ia: Area Under the Curve (AUC) of a serum concentration versus time profile

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 weeks

  2. Ia: Area Under the Curve of a serum concentration to infinite time (AUC0-infinity)

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 weeks

  3. Ia: Maximum concentration (Cmax) of YK012

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 weeks

  4. Ia: Time to reach Cmax (Tmax)

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 weeks

  5. Ia: Elimination half life (t1/2)

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 weeks

  6. Ia: Total Apparent Clearance (CL)

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 weeks

  7. Ia: Apparent volume of distribution(Vd)

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 weeks

  8. Ia: Minimum Concentration (Cmin) of YK012

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 weeks

  9. Ia: The duration of peripheral blood B-cell depletion

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 weeks

  10. Ia: The profile of peripheral blood NK cell changes

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 weeks

  11. Ia: The profile of peripheral blood T-cell changes

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 weeks

  12. Ia: The profile of cytokine changes

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 weeks

  13. Ia: ADA (anti-drug antibody) and Nab (Neutralizing antibody) positivity rate

    Time frame: From 1 hour before the first infusion of YK012 to the end of trial at 53 weeks

  14. 24-hour urine protein change

    Time frame: From enrollment to the end of the trial at 53 or 77 (if applicable) weeks

  15. eGFR (Glomerular Filtration Rate) change

    Time frame: From enrollment to the end of the trial at 53 or 77 (if applicable) weeks

  16. Anti-PLA2R antibody titer change

    Time frame: From enrollment to the end of the trial at 53 or 77 (if applicable) weeks

  17. Ia: Proportion of participants achieving overall response

    Time frame: From enrollment to the end of the trial at 53 weeks

  18. Proportion of participants achieving CR or PR

    Time frame: From enrollment to the end of the trial at 53 or 77 (if applicable) weeks

  19. Proportion of anti-PLA2R antibody-positive participants achieving immunological remission

    Time frame: From enrollment to the end of the trial at 53 or 77 (if applicable) weeks

  20. Time to achieve complete renal remission

    Time frame: From enrollment to the end of the trial at 53 or 77 (if applicable) weeks

  21. Time to achieve overall renal response

    Time frame: From enrollment to the end of the trial at 53 or 77 (if applicable) weeks

  22. Duration of complete renal response

    Time frame: From enrollment to the end of the trial at 53 or 77 (if applicable) weeks

  23. Duration of overall renal response

    Time frame: From enrollment to the end of the trial at 53 or 77 (if applicable) weeks

  24. Proportion of participants with treatment failure

    Time frame: From enrollment to the end of the trial at 53 or 77 (if applicable) weeks

  25. Proportion of participants with relapse

    Time frame: From enrollment to the end of the trial at 53 or 77 (if applicable) weeks

  26. Ib: Adverse Event (AE)

    An AE is defined as any untoward medical event that occurs after a participant receives the investigational drug, which may be manifested as symptoms, signs, diseases, or laboratory abnormalities, but may not necessarily have a causal relationship with the investigational drug.

    Time frame: From the first induction to the end of the trial at 53 or 77 (if applicable) weeks

  27. Ib: Severe Adverse Event

    An SAE refers to any untoward medical occurrence after the participant receives the IMP that results in one or more of the following: death, life-threatening event, permanent or serious disability or loss of function, need for hospitalization or prolongation of hospitalization, congenital abnormalities or birth defects.

    Time frame: From the first induction to the end of the trial at 53 or 77 (if applicable) weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 21, 2025
StartActual
Mar 8, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06982729
Lead sponsor
Excyte Biopharma Ltd
Responsible party
Sponsor
First posted
May 21, 2025
Start date
Mar 8, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 17, 2025

Study contacts

Minghui Zhao, M.D.
Contact
mhzhao@bjmu.edu.cn
+86-010-83572388
Minghui Zhao, M.D.
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: YK012

Start the discussion